Myriad Genetics , a leader in molecular diagnostics and precision medicine, has entered into a strategic collaboration with SOPHiA GENETICS , an AI-driven company transforming precision medicine. The partnership aims to co-develop and deliver an innovative global liquid biopsy companion diagnostic (CDx) test for pharmaceutical companies.
The initiative will combine Myriad’s advanced U.S.-based laboratory expertise to support global clinical trial testing with SOPHiA GENETICS’ decentralized network of over 800 institutions across 70+ countries to facilitate worldwide deployment.
“Serving patients and healthcare providers along the cancer care continuum is a strategic focus for Myriad Genetics,” said Sam Raha, President and CEO, Myriad Genetics. "We expect this collaboration with SOPHiA GENETICS to support the development and global commercialization of comprehensive CDx solutions for our BioPharma partners with the potential to positively impact patient lives, add an important product offering to the Myriad menu and support the growth of our CDx programs."
The collaboration will initially focus on MSK-ACCESS® powered with SOPHiA DDM™, a cutting-edge liquid biopsy test created in collaboration with Memorial Sloan Kettering Cancer Center. This test analyzes circulating tumor DNA (ctDNA) from a single blood draw to identify actionable genomic alterations using proprietary algorithms. Transforming this application into a CDx will enable broader patient access to precision oncology solutions at scale.
Under the agreement, Myriad will oversee regulatory submissions in the U.S., while SOPHiA GENETICS will lead submissions internationally. Both companies will jointly engage in development efforts, adopting a hybrid model designed to deliver pharmaceutical partners access to major regulated markets.
“This collaboration represents a pivotal moment for the industry,” said Jurgi Camblong, Co-founder and CEO of SOPHiA GENETICS. “By combining the complementary strengths of a specialty lab leader and a global testing network, we are not only expanding access to innovative oncology testing but also laying the foundation for a new hybrid model in companion diagnostics. This collaboration will allow us to serve both clinical and pharmaceutical partners better, while accelerating the adoption of liquid biopsy solutions across key markets.”
Further insights into the partnership will be shared during a joint panel discussion at the World CB and CDx Summit in Boston.